Sangamo BioSciences | SGMO - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Alaunos Therapeutics USD -1.01M 175K 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Amgen USD 4.61B 777M 2026-06
Bayer EUR 827M 2.7B 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Cipla INR 8.88B 2.74B 2026-06
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD -9.02M 65.06M 2026-03
CSL USD 2.64B 1.97B 2025-12
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Grifols EUR 320.55M 91.01M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 7.48B 860M 2026-06
Karyopharm Therapeutics USD -26.76M 8.92M 2026-03
Merck USD 840M 2.72B 2026-06
Novartis USD 4.75B 515M 2026-06
Omeros USD -35.41M 23.75M 2024-09
Pfizer USD 667M 4.32B 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 2.38B 449M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Tectonic Therapeutic USD -27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06